Canada’s Aeterna Zentaris Inc. said the U.S. FDA approved its oral test to diagnose adult growth hormone deficiency.
Genentech announced that the U.S. FDA approved Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.
Bristol-Myers Squibb Receives FDA Approval for Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration approved Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
The last several years has shown a particular focus on immuno-oncology therapies, probably as close to miracle cures as anything seen in recent years. Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.
France’s competition authority fined U.S. healthcare group Johnson & Johnson 25 million euros ($29.6 million) after it ruled the company had deliberately slowed market access to generic copies of its painkiller Durogesic.
Orchard Therapeutics said it raised $110 million in the second round of funding as the drug developer looks to launch its gene therapy to treat a rare inherited disorder and beef up manufacturing facilities.
South Korea’s Samsung Bioepis said the U.S. FDA accepted for review its copy of Roche’s blockbuster breast cancer drug Herceptin for potential approval.
Carmel Biosciences Inc. received final approval of its New Drug Application from the U.S. Food and Drug Administration for Prexxartan (valsartan) oral solution.
Cancer treatments from Pfizer Inc. and Exelixis Inc. won expanded approval from the U.S. FDA for use in previously untreated patients.
Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
Biogen and Ionis Pharmaceuticals announced that they entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal. The Bay Area company inked a multi-year collaborative agreement with Genentech to discover new small molecules.
Shire’s experimental treatment SHP609 to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial.
The FDA approved Spark Therapeutics’ treatment for a rare form of blindness, marking the first time the U.S. regulatory agency approved a gene therapy for an inherited disease.
The world’s largest chocolate makers are looking for ways to keep increasingly health-conscious consumers coming back for more.
U.S. health insurer Humana Inc. and two private equity firms agreed to buy home healthcare and long-term care operator Kindred Healthcare Inc. for about $810 million, the latest expansion by an American health insurer into patient care.
Dr. Reddy’s Laboratories will pay $5 million to resolve claims that the Indian company sold prescription drugs in the U.S. in packaging not tested for child safety.
The FDA approved Aerie Pharmaceuticals Inc.’s eyedrop Rhopressa as a treatment for glaucoma, two months ahead of the expected date.
Intouch Solutions, a leading marketing agency serving the pharmaceutical industry, announced the promotion of five employees in its Chicago office.
Novartis picked up a priority review voucher in a $130 million deal with California-based Ultragenyx Pharmaceutical Inc. The PRV is for rare pediatric diseases.
Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.